Replace Therapeutics

Replace Therapeutics is a private biotechnology company that is developing a novel PGI method capable of inserting and deleting small DNA sequences. Replace Therapeutics was founded by serial entrepreneur Dr. Shakke Halperin. The technology combines the site-specificity of CRISPR/Cas9 with the writing enzyme DNA ligase to precisely manipulate small DNA sequences. This ligase-mediated PGI (L-PGI) technology is well-suited for editing DNA base pairs in the range of 10 to 100, complementing Tome's flagship large DNA PGI technology—integrase-mediated PGI (I-PGI). In in vitro studies, L-PGI has demonstrated high efficiency and specificity in both dividing and non-dividing cells without the need for double-strand DNA breaks.